Last updated on July 15th, 2024 at 04:30 am
New allegations have surfaced against Dr. Richard Ogden Roberts III, a pediatric endocrinologist at the Texas Children’s Hospital, who is under scrutiny for administering puberty blocking and cross-sex hormone medications to young patients diagnosed with gender dysphoria. Furthermore, Roberts was instrumental in a lawsuit seeking to halt a ban on child sex changes, often working with radical activist organizations.
The recent allegations accuse Roberts of committing Medicaid fraud. A whistleblower at the hospital alleged that the institution is illegally billing Medicaid for transgender procedures. In compliance with state law, which strictly prohibits the use of Medicaid funds for any procedures aiming to alter an individual’s sex, Texas Attorney General Ken Paxton has initiated an investigation into Roberts’ activities.
Simultaneously, scrutiny into Roberts’ attempt to cease the Texas ban on child sex changes brought to light his connections with far-left ideologues, activist groups, and pharmaceutical companies that could potentially profit from gender dysphoria treatments. For instance, Roberts is a member of the GLMA: Health Professionals Advancing LGBTQ+ Equality group, which mapped legislation allegedly harming transgender youth access to medical care.
Among the funding sources of these activist groups are pharmaceutical giants, many of which manufacture drugs linked to gender transition. For instance, the GLMA is sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents various companies including AbbVie, Bayer, Pfizer, Teva US Specialty Medicines, and Eli Lilly. Thus, these relationships indicate a concerning confluence of medical, ideological, and commercial interests in the arena of child gender dysphoria treatments.
Discussion about this post